F. Teixeira

P. Rodrigues-Santos1
L. Belo1
J. Sereno1
Learn More
OBJECTIVE Recombinant human erythropoietin (rhEPO) therapy under circumstances of moderate chronic renal failure (CRF), with yet lower kidney and heart lesion, may have a protective cardiac effect beyond the correction of anemia, whose mechanism deserves better elucidation, namely by clarifying the impact on gene expression profile of markers of apoptosis,(More)
  • 1